4-1BBL as a Mediator of Cross-Talk between Innate,Adaptive, and Regulatory Immunity against Cancer |
| |
| Authors: | Alejandra G. Martinez-Perez Jose J. Perez-Trujillo Rodolfo Garza-Morales Maria J. Loera-Arias Odila Saucedo-Cardenas Aracely Garcia-Garcia Humberto Rodriguez-Rocha Roberto Montes-de-Oca-Luna |
| |
| Affiliation: | 1.Department of Histology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, Mexico; (A.G.M.-P.); (J.J.P.-T.); (M.J.L.-A.); (O.S.-C.); (A.G.-G.); (H.R.-R.);2.Internal Medicine Residency Program, University of Texas Rio Grande Valley, Edinburg, TX 78539, USA;3.Department of Molecular Genetics, Northeast Biomedical Research Center, Mexican Institute of Social Security (IMSS), Monterrey 64000, Mexico |
| |
| Abstract: | The ability of tumor cells to evade the immune system is one of the main challenges we confront in the fight against cancer. Multiple strategies have been developed to counteract this situation, including the use of immunostimulant molecules that play a key role in the anti-tumor immune response. Such a response needs to be tumor-specific to cause as little damage as possible to healthy cells and also to track and eliminate disseminated tumor cells. Therefore, the combination of immunostimulant molecules and tumor-associated antigens has been implemented as an anti-tumor therapy strategy to eliminate the main obstacles confronted in conventional therapies. The immunostimulant 4-1BBL belongs to the tumor necrosis factor (TNF) family and it has been widely reported as the most effective member for activating lymphocytes. Hence, we will review the molecular, pre-clinical, and clinical applications in conjunction with tumor-associated antigens in antitumor immunotherapy, as well as the main molecular pathways involved in this association. |
| |
| Keywords: | 4-1BBL cancer immunology immunotherapy cancer therapy cancer vaccination |
|
|
